Filament is one of a small number of Canadian companies to have Good Manufacturing Practices-compliant psilocybin drug candidates entering Health Canada-approved clinical trials
VANCOUVER, BC, Jan. 26, 2022 /CNW/ –Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced that its wholly-owned subsidiary Psilo Scientific Ltd. has been included in Health Canada’s list of licensed psilocybin producers. This list is available upon request to parties interested in access to psilocybin through the Special Access Program (SAP) or for scientific research. The SAP allows health care practitioners to request for patients, on an emergency basis, access to drugs that are not yet approved in Canada, such as psilocybin and psilocin.
“Our inclusion in this list will aid us in adding to our growing number of partnerships in the Canadian psychedelic ecosystem,” said Benjamin Lightburn, Chief Executive Officer of Filament Health. “We commend Health Canada on their continuing support of the SAP and of scientific research into psychedelics.”
The list of approved psilocybin producers is intended to support researchers looking to access psilocybin for the purpose of conducting clinical trials in Canada and practitioners looking for psilocybin for emergency treatment of a patient under the SAP.
For more information about the SAP and Filament Health, contact firstname.lastname@example.org or visit www.filament.health/health-canada-special-access-program.
ABOUT FILAMENT HEALTH (OTCQB:FLHLF) (NEO:FH) (FSE:7QS)
Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates.
FORWARD LOOKING INFORMATION
Certain statements and information contained herein may constitute “forward-looking statements” and “forward-looking information,” respectively, under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as, “expect”, “anticipate”, “continue”, “estimate”, “may”, “will”, “should”, “believe”, “intends”, “forecast”, “plans”, “guidance” and similar expressions are intended to identify forward-looking statements or information. Forward-looking statements herein include, but are not limited to, statements regarding the benefits of psilocin as compared to psilocybin. The forward-looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward-looking statements. Forward-looking statements regarding the Company are based on the Company’s estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including results of the clinical trial. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Filament will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws.
SOURCE Filament Health Corp.
For further information: MEDIA RELATIONS: Anna Cordon, Director of Communications, 778.245.9067, email@example.com; INVESTOR RELATIONS: KCSA Strategic Communications, Tim Regan/Adam Holdsworth, 347.487.6788, KCSAfirstname.lastname@example.org